{"text": ["10", "Best", "Dividend", "Stocks", "to", "Buy", "in", "August"], "created_at": "2021-08-04 18:43:04"}
{"text": ["JAMA", "Dermatology", "Publishes", "Data", "Showing", "RINVOQ\u00ae", "(upadacitinib)", "Achieved", "Superiority", "Versus", "DUPIXENT\u00ae", "(dupilumab)", "for", "Primary", "and", "All", "Ranked", "Secondary", "Endpoints", "in", "Phase", "3b", "Head-to-Head", "Study", "in", "Adults", "with", "Atopic", "Dermatitis"], "created_at": "2021-08-04 16:01:00"}
{"text": ["10", "Best", "Dividend", "Paying", "Stocks", "to", "Buy", "Now"], "created_at": "2021-08-04 14:32:49"}
{"text": ["Dividend", "Aristocrats", "AbbVie,", "Exxon", "Mobil", "and", "IBM", "Are", "Three", "Good", "Buys"], "created_at": "2021-08-04 07:15:00"}
